3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohex anecarbonyl-amino butyric acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis

Details for Australian Patent Application No. 2004215672 (hide)

International Classifications

Event Publications

15 September 2005 PCT application entered the National Phase

PCT publication WO2004/076426 Priority application(s): WO2004/076426

22 December 2005 Assignment before Grant

Aventis Pharma Deutschland GmbH The application has been assigned to Sanofi-Aventis Deutschland GmbH

7 January 2010 Application Accepted

Published as AU-B-2004215672

6 May 2010 Standard Patent Sealed

15 September 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.